Company News 

Litigation boost for Allergy Therapeutics

Litigation boost for Allergy Therapeutics

Good news for shareholders in Allergy Therapeutics (AGY) as the immunology business revealed that earnings for FY2019 will come in ahead of market expectations on the back of solid sales growth, particularly in Spain, the Netherlands and Switzerland, together with an intensified focus on cost efficiencies and a lower R&D bill.

To continue reading, subscribe today

and enjoy unlimited access to the following:

  • Tips of the Week
  • Funds coverage
  • Weekly features on big investment themes
  • Trading ideas
  • Comprehensive companies coverage
  • Economic analysis
Subscribe to Investors Chronicle

Related topics

Subscribe today

Full access for just £3.37 a week:

• Tips and recommendations - to beat the market 
• Portfolio clinic & Mr Bearbull - build a well-planned portfolio 
• Expert tools - track and manage investments effortlessly
• Plus free delivery to your home or office

Subscribe Now